Adding PD1 Inhibitor to Neoadjuvant Chemotherapy Significantly Increases the pCR Rate in High-Risk, Early-Stage ER-positive, HER2-negative Breast Cancer By Ogkologos - February 12, 2025 1024 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 7FL and KEYNOTE-756 studies Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR New on NCI’s Websites for January 2020 January 2, 2020 EMA Recommends Granting a Marketing Authorisation for Decitabine / Cedazuridine August 31, 2023 ESMO Advocates for EU Legislation to Prevent Oncologist Burnout and Ensure... June 23, 2025 Aiming to support a robust regulatory ecosystem for driving cancer research... May 12, 2026 Load more HOT NEWS Treatment for Children with Leukemia Also Effective for Adolescents, Young Adults Estimate of the Global Economic Cost of the Most Prevalent Cancers... Adjuvant Immunotherapy Approved for Some Patients with Lung Cancer New Immunotherapy Option Approved for Cervical Cancer, Rare Lymphoma
